KSHV microRNAs in tumor invasion and angiogenesis
KSHV microRNAs in tumor invasion and angiogenesis
批准号:
10264784
负责人:
Shou-Jiang Gao
金额:
$18.97万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-03-03 至 2022-02-28
关键词:
Acquired Immunodeficiency SyndromeBindingCellsChinaClinical TrialsCoupledDevelopmentEtiologyFundingG protein coupled receptor kinaseGenomeGlutamic AcidGoalsHerpesviridae InfectionsHighly Active Antiretroviral TherapyHumanHuman Herpesvirus 8IndividualKaposi SarcomaLaboratoriesMalignant - descriptorMalignant NeoplasmsMediatingMesenchymal Stem CellsMicroRNAsModelingMolecularMorbidity - disease rateMulticentric Angiofollicular Lymphoid HyperplasiaMutagenesisMutateOrganPathologicPathway interactionsPatientsPhosphotransferasesPreventionProteinsProto-Oncogene Proteins c-aktRoleSH3 DomainsSTAT3 geneSignal TransductionSiteSocietiesTherapeuticTimeTumor AngiogenesisTumor Cell InvasionViralVisceralangiogenesiscellular targetinginhibitor/antagonistinnovationinsightmortalitynovelnovel therapeutic interventionoverexpressionprimary effusion lymphomaprogramsreceptortherapeutic targettumortumorigenesis
中文摘要
卡波西肉瘤相关疱疹病毒(KSHV)是几种常见癌症的病原学致病因子,尽管发病率很高。
积极的抗逆转录病毒疗法,如卡波西肉瘤(KS),仍然是艾滋病患者的主要癌症。
KS的显著病理特征是过度放松对血管生成的控制,以及极端的侵袭性。
表现为多灶性肿瘤和内脏脏器受累,从而加深了对其分子生物学基础的认识。
KSHV诱导的血管生成和细胞侵袭能力的研究可作为我们开发新型治疗药物的基础。
方法。我们的第一个美国-中国的协作项目团队由上一个美国-中国项目的前一个周期项目提供资金。
在实现这一目标方面取得了重大进展,包括:1)开发了一种全新的人类和初级卫生组织KSHV感染模型。
间充质干细胞(MSCs),其中KSHV可诱导血管生成、细胞侵袭和恶性转化。
转化和肿瘤发生密切地模仿人类的KS和肿瘤;;(2)展示了KS和KS的基本作用。
KSHV和microRNAs(MiRNAs)在KSHV诱导的血管生成和细胞侵袭中发挥作用;;(3)在鉴定KSHV的miR-n6-mi3p。
作为一种促进血管生成的miRNA基因,它通过靶向SH3结构域结合的富含谷氨酸的基因来诱导血管生成。
蛋白质组(SH3BGR)激活信号转导通路;;和4)证实KSHV信号转导通路miR-nK3-5p促进细胞生长。
通过靶向G蛋白偶联的受体蛋白激酶2(GRK2)来激活AKT信号通路的侵袭。我们建议采取措施。
将这些令人兴奋的新发现加以扩展,以期在此之前进一步剖析它们的分子生物学机制。
KSHV和miRNAs可以通过诱导血管生成和细胞侵袭来促进肿瘤的发生,从而进一步探索肿瘤的发生机制。
这些发现的治疗和应用前景。其核心假说是,KSHV编码特定的miRNAs。
为了更好地激活血管生成基因和侵袭性基因通路,从而促进KSHV诱导的肿瘤发生、发展和死亡。
靶向这些途径可以有效地抑制KSHV诱导的癌症的发展。我们将无法识别。
KSHV和miRNAs可以介导KSHV诱导的血管生成,并定义其作用机制(Aim:1);;。
识别KSHV和miRNAs,它们可能介导KSHV诱导的细胞侵袭,并定义其作用机制(Aim:2);;。
描绘了促血管生成基因和支持侵袭的miRNAs在促进肿瘤的发展过程中的重要作用,以及在肿瘤中的作用。
血管生成和侵袭性研究(Aim);;研究并将探索靶向肿瘤血管生成和侵袭的新的治疗和应用前景。
侵袭性基因通路由KSHV和miRNAs在KSHV诱导的肿瘤发生机制(AIM 4)中激活。这一新的应用程序将。
进一步加强两位美国队和中国主席团队的合作努力,具有高度互补性的专业知识。
为了更好地加快新提出的项目的进展,我们认为,如果不是这样,我们就很难通过个人努力来实现这一目标。
实验室。从这个项目中获得的成果将是非常重要的技术和创新技术,因为它们将是最重要的。
首次明确了KSHV和miRNAs在肿瘤血管生成和侵袭中的作用机制。
在一个真正的KS治疗模式中,他们和他们确定了一些新的治疗目标,用于进一步开发新的创新的治疗方法。
因此,我们还将建立一种全新的癌症发生范式模型,通过病毒或颠覆MmiRNA途径来介导肿瘤发生。
为了解其他癌症的致癌机制提供了更多的见解。
英文摘要
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiologic agent of several cancers. Despite highly
active anti-retroviral therapy, Kaposi’s sarcoma (KS) remains as a dominant cancer in AIDS patients. The
hallmark pathological features of KS are excessive deregulation of angiogenesis and extreme invasiveness
manifested as multifocal tumors and involvement of visceral organs. Thus, understanding the molecular basis
of KSHV-induced angiogenesis and cell invasion could serve as the basis for developing novel therapeutic
approaches. Our US-China collaborative team funded by previous cycle of the US-China Program has made
significant progresses toward this goal by 1) developing a novel model of KSHV infection of human primary
mesenchymal stem cells (MSCs), in which KSHV induces angiogenesis, cell invasion, malignant
transformation and tumorigenesis closely mimicking human KS tumors;; 2) demonstrating the essential roles of
KSHV microRNAs (miRNAs) in KSHV-induced angiogenesis and cell invasion;; 3) identifying KSHV miR-K6-3p
as a pro-angiogenic miRNA that induces angiogenesis by targeting SH3 domain-binding glutamic acid-rich
protein (SH3BGR) to activate the STAT3 pathway;; and 4) demonstrating that KSHV miR-K3-5p promotes cell
invasion by targeting G-protein coupled receptor kinase 2 (GRK2) to activate the AKT signaling. We propose to
extend these exciting discoveries with the objective to further dissect the molecular mechanisms by which
KSHV miRNAs promote tumorigenesis by inducing angiogenesis and cell invasion, and to explore the
therapeutic application of these discoveries. The central hypothesis is that KSHV encodes specific miRNAs
to activate angiogenic and invasive pathways contributing to KSHV-induced tumorigenesis, and as a result,
targeting these pathways can effectively inhibit the development of KSHV-induced cancers. We will identify
KSHV miRNAs that mediate KSHV-induced angiogenesis and define the mechanisms of action (Aim 1);;
identify KSHV miRNAs that mediate KSHV-induced cell invasion and define the mechanisms of action (Aim 2);;
delineate the roles of pro-angiogenic and pro-invasive miRNAs in the development of tumors, and in tumor
angiogenesis and invasion (Aim 3);; and explore the therapeutic application of targeting angiogenic and
invasive pathways activated by KSHV miRNAs in KSHV-induced tumorigenesis (Aim 4). This application will
further reinforce the collaborative efforts of the two US and China teams with highly complementary expertise
to accelerate the advancements of the proposed project that are otherwise difficult to achieve by the individual
laboratories. The results from this project will be highly significant and innovative because they will, for the
first time, define the functions and mechanisms of action of KSHV miRNAs in tumor angiogenesis and invasion
in a genuine KS model, and identify novel targets for developing innovative therapeutic approaches. The study
will also establish a novel paradigm of oncogenesis mediated by viral subversion of the miRNA pathway, thus
providing insights into the oncogenesis of other cancers.
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
Correction: A viral microRNA downregulates metastasis suppressor CD82 and induces cell invasion and angiogenesis by activating the c-Met signaling.
更正:病毒 microRNA 下调转移抑制因子 CD82,并通过激活 c-Met 信号传导诱导细胞侵袭和血管生成。
DOI:
10.1038/s41388-021-01823-4
发表时间:
2021
期刊:
Oncogene
影响因子:
8
作者:
[Li,W, Hu,M, Wang,C, Lu,H, Chen,F, Xu,J, Shang,Y, Wang,F, Qin,J, Yan,Q, Krueger,BJ, Renne,R, Gao,S-J, Lu,C]
通讯作者:
Lu,C
CircRNA ARFGEF1 functions as a ceRNA to promote oncogenic KSHV-encoded viral interferon regulatory factor induction of cell invasion and angiogenesis by upregulating glutaredoxin 3.
CircRNA ARFGEF1 作为 ceRNA 发挥作用,通过上调谷氧还蛋白 3 促进致癌 KSHV 编码的病毒干扰素调节因子诱导细胞侵袭和血管生成
DOI:
10.1371/journal.ppat.1009294
发表时间:
2021-03
期刊:
PLoS pathogens
影响因子:
6.7
作者:
[Yao S, Jia X, Wang F, Sheng L, Song P, Cao Y, Shi H, Fan W, Ding X, Gao SJ, Lu C]
通讯作者:
Lu C
Immune evasion strategy involving propionylation by the KSHV interferon regulatory factor 1 (vIRF1).
DOI:
10.1371/journal.ppat.1011324
发表时间:
2023-04
期刊:
PLoS pathogens
影响因子:
6.7
作者:
[]
通讯作者:
Citrulline-urea cycle in KSHV cellular transformation
-
批准号:10634838
-
项目类别:
-
资助金额:$54.05万
-
财政年份:2023
-
负责人:Shou-Jiang Gao
-
依托单位:
Impact of microbiota on AIDS-Kaposi’s sarcoma development and therapy
-
批准号:10753890
-
项目类别:
-
资助金额:$79.31万
-
财政年份:2023
-
负责人:Shou-Jiang Gao
-
依托单位:
Regulation of KSHV replication by N6-methyladenosine (m6A) - Diversity Supplement
-
批准号:10533427
-
项目类别:
-
资助金额:$9.77万
-
财政年份:2022
-
负责人:Shou-Jiang Gao
-
依托单位:
HISTONE MODIFIERS IN ORAL KSHV INFECTION AND MALIGNANCIES
-
批准号:9756364
-
项目类别:
-
资助金额:$39.13万
-
财政年份:2018
-
负责人:Shou-Jiang Gao
-
依托单位:
KSHV microRNAs in tumor invasion and angiogenesis
-
批准号:9906178
-
项目类别:
-
资助金额:$18.97万
-
财政年份:2017
-
负责人:Shou-Jiang Gao
-
依托单位:
KSHV microRNAs in tumor invasion and angiogenesis
-
批准号:9243868
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2017
-
负责人:Shou-Jiang Gao
-
依托单位:
Targeting KSHV malignancies and persistent infection
-
批准号:8943348
-
项目类别:
-
资助金额:$37.72万
-
财政年份:2015
-
负责人:Shou-Jiang Gao
-
依托单位:
HISTONE MODIFIERS IN ORAL KSHV INFECTION AND MALIGNANCIES
-
批准号:9257374
-
项目类别:
-
资助金额:$41.25万
-
财政年份:2015
-
负责人:Shou-Jiang Gao
-
依托单位:
HISTONE MODIFIERS IN ORAL KSHV INFECTION AND MALIGNANCIES
-
批准号:9108377
-
项目类别:
-
资助金额:$41.25万
-
财政年份:2015
-
负责人:Shou-Jiang Gao
-
依托单位:
KSHV microRNAs in cellular transformation and tumorigenesis
-
批准号:8728172
-
项目类别:
-
资助金额:$19.46万
-
财政年份:2013
-
负责人:Shou-Jiang Gao
-
依托单位:
KSHV microRNAs in cellular transformation and tumorigenesis
-
批准号:8899469
-
项目类别:
-
资助金额:$20.12万
-
财政年份:2013
-
负责人:Shou-Jiang Gao
-
依托单位:
KSHV microRNAs in cellular transformation and tumorigenesis
-
批准号:8546896
-
项目类别:
-
资助金额:$20.01万
-
财政年份:2013
-
负责人:Shou-Jiang Gao
-
依托单位:
CELL MODEL FOR KSHV INFECTION AND GENETIC MANIPULATION
-
批准号:7957694
-
项目类别:
-
资助金额:$0.33万
-
财政年份:2009
-
负责人:Shou-Jiang Gao
-
依托单位:
Mechanism of KSHV-induced angiogenesis
-
批准号:8311370
-
项目类别:
-
资助金额:$25.31万
-
财政年份:2008
-
负责人:Shou-Jiang Gao
-
依托单位:
Mechanism of KSHV-induced angiogenesis
-
批准号:9242565
-
项目类别:
-
资助金额:$39.19万
-
财政年份:2008
-
负责人:Shou-Jiang Gao
-
依托单位:
Mechanism of KSHV-induced angiogenesis
-
批准号:7612782
-
项目类别:
-
资助金额:$30.77万
-
财政年份:2008
-
负责人:Shou-Jiang Gao
-
依托单位:
Mechanism of KSHV-induced angiogenesis
-
批准号:8012899
-
项目类别:
-
资助金额:$4.84万
-
财政年份:2008
-
负责人:Shou-Jiang Gao
-
依托单位:
Mechanism of KSHV-induced angiogenesis
-
批准号:8018127
-
项目类别:
-
资助金额:$9.6万
-
财政年份:2008
-
负责人:Shou-Jiang Gao
-
依托单位:
Mechanism of KSHV-induced angiogenesis
-
批准号:8210868
-
项目类别:
-
资助金额:$32.93万
-
财政年份:2008
-
负责人:Shou-Jiang Gao
-
依托单位:
ORAL KSHV (KAPOSI'S SARCOMA HERPES VIRUS) COMPLICATIONS IN HIV INFECTION
-
批准号:7718685
-
项目类别:
-
资助金额:$4.6万
-
财政年份:2008
-
负责人:Shou-Jiang Gao
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: